Glassman Wealth Services’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Glassman Wealth Services’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$1K	–	1587
2020 Q3	$1K	Hold	200	–	–	﹤0.01%	1293
2020 Q2	$1K	Buy	+200	New	+$824	﹤0.01%	1175
2018 Q3	–	Sell	-20	Closed	–	–	1009
2018 Q2	$0	Buy	+20	New	+$349	﹤0.01%	1007
2018 Q1	–	Sell	-10	Closed	–	–	987
2017 Q4	$0	Buy	+10	New	+$322	﹤0.01%	842

Other funds holding FPRX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glassman Wealth Services's FPRX Position: Q4 2020 in Review

Glassman Wealth Services sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 200 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in FPRX in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2020. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

Glassman Wealth Services reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Glassman Wealth Services sold 200 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $1K.
Glassman Wealth Services first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
Glassman Wealth Services's Five Prime Therapeutics, Inc. position peaked at $1K in Q3 2020.
125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on Glassman Wealth Services's 13F filing for Q4 2020, filed 4 Feb 2021.